RxDoctor Payments Data

James Levine, DO

Rheumatology · Greeley, CONPI 1093793838

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $81,286 of the $129,926 with a category attached, or 62.6%. 14 manufacturers reported payments, led by Sanofi at 42.8% of the total. Among rheumatology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$129,926in general payments, 2019–2025

Across 349 payments — averaging $372.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$56K
  • Lilly USA, LLC$52K
  • Novartis$6K
  • Gilead$6K
  • Regeneron Healthcare Solutions, Inc.$4K
  • Amgen$3K
  • plus $3K from 8 others

What the payments were for

  • Consulting fees$24,35919%
  • Speaking & faculty fees$81,28663%
  • Travel & lodging$16,08612%
  • Food & beverage$8,1626%
  • Education$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$129,926 in reported general payments places this provider in the 95th percentile of 108 rheumatology providers in Colorado.

See all rheumatology providers in Colorado

Medicare billing

Part B allowed, 2024
$3,190,127
Medicare patients
673
Services billed
210,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab89$648,016
RinvoqUpadacitinib34$235,163
Enbrel SureclickEtanercept23$204,007
OtezlaApremilast32$161,225
Humira PenAdalimumab15$120,487
Cimzia (2 Pack)Certolizumab Pegol19$106,449
ActemraTocilizumab19$103,689
KevzaraSarilumab21$90,881
KineretAnakinra13$72,460
MethotrexateMethotrexate Sodium685$17,384
Hydroxychloroquine Sulfate331$15,617
Leflunomide194$11,148
Xtampza ErOxycodone Myristate19$10,975
Mycophenolate Mofetil78$7,643
Cevimeline Hcl15$3,314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$468$235,16334 claims
AmgenOtezla$3,169$161,22532 claims
UCB, Inc.Cimzia (2 Pack)$521$106,44919 claims
SanofiKevzara$55,553$90,88121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 108 rheumatology providers in Colorado.

Other rheumatology in Greeley

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →